| Previous close | 5.40 |
| Open | 5.53 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 5.53 - 5.57 |
| 52-week range | 3.53 - 11.00 |
| Volume | 1,200 |
| Avg. volume | 5,377 |
| Market cap | 283.764M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Compass Therapeutics, Inc. to Acquire TRIGR Therapeutics, Inc.
Compass Therapeutics to Acquire TRIGR Therapeutics to Obtain Global Rights to a differentiated bispecific antibody targeting both DLL4 and VEGF-A
- Business Wire
Compass Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Compass Therapeutics, Inc. (OTCQB: CMPX), a clinical-stage biotechnology company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies, today reported fourth quarter and full year 2020 financial results and provided a business update.
- Business Wire
Compass Therapeutics Announces Participation in March 2021 Investor Conferences
Compass Therapeutics, Inc. (OTCQB: CMPX), a clinical-stage biotechnology company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies, today announced that Thomas Schuetz, MD, PhD, Co-Founder and Chief Executive Officer of Compass Therapeutics, will participate in the following virtual investor conferences:
